Literature DB >> 24839622

Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Geoffrey C Nguyen, Shane M Devlin, Waqqas Afif, Brian Bressler, Steven E Gruchy, Gilaad G Kaplan, Liliana Oliveira, Sophie Plamondon, Cynthia H Seow, Chadwick Williams, Karen Wong, Brian M Yan, Jennifer Jones.   

Abstract

BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In Canada, where universal health care can vary significantly among provinces, quality indicators can be used to identify potential gaps in the delivery of IBD care and standardize the approach to interprovincial management.
METHODS: The Emerging Practice in IBD Collaborative (EPIC) group generated a shortlist of IBD quality indicators based on a comprehensive literature review. An iterative voting process was used to select quality indicators to take forward. In a face-to-face meeting with the EPIC group, available evidence to support each quality indicator was presented by the EPIC member aligned to it, followed by group discussion to agree on the wording of the statements. The selected quality indicators were then ratified in a final vote by all EPIC members.
RESULTS: Eleven quality indicators for the management of IBD within the single-payer health care system of Canada were developed. These focus on accurate diagnosis, appropriate and timely management, disease monitoring, and prevention or treatment of complications of IBD or its therapy.
CONCLUSIONS: These quality indicators are measurable, reflective of the evidence base and expert opinion, and define a standard of care that is at least a minimum that should be expected for IBD management in Canada. The next steps for the EPIC group involve conducting research to assess current practice across Canada as it pertains to these quality indicators and to measure the impact of each of these indicators on patient outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24839622      PMCID: PMC4049258          DOI: 10.1155/2014/941245

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  153 in total

1.  ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease.

Authors:  Jonathan A Leighton; Bo Shen; Todd H Baron; Douglas G Adler; Raquel Davila; James V Egan; Douglas O Faigel; Seng-Ian Gan; William K Hirota; David Lichtenstein; Waqar A Qureshi; Elizabeth Rajan; Marc J Zuckerman; Trina VanGuilder; Robert D Fanelli
Journal:  Gastrointest Endosc       Date:  2006-04       Impact factor: 9.427

2.  Screening and surveillance colonoscopy in chronic Crohn's colitis.

Authors:  S Friedman; P H Rubin; C Bodian; E Goldstein; N Harpaz; D H Present
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients.

Authors:  Roshan Razik; Charles N Bernstein; Justina Sam; Reka Thanabalan; Geoffrey C Nguyen
Journal:  Can J Gastroenterol       Date:  2012-11       Impact factor: 3.522

5.  Postoperative complications and mortality following colectomy for ulcerative colitis.

Authors:  Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan
Journal:  Clin Gastroenterol Hepatol       Date:  2011-07-30       Impact factor: 11.382

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 7.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Authors:  Eliza Prefontaine; John K Macdonald; Lloyd R Sutherland
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission.

Authors:  Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross
Journal:  Am J Gastroenterol       Date:  2009-03-24       Impact factor: 10.864

9.  Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.

Authors:  H Yuhara; C Steinmaus; D Corley; J Koike; M Igarashi; T Suzuki; T Mine
Journal:  Aliment Pharmacol Ther       Date:  2013-04-02       Impact factor: 8.171

10.  Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.

Authors:  Onur Baser; Xianchen Liu; Hemant Phatak; Li Wang; Jack Mardekian; Hugh Kawabata; Danielle Petersel; Melissa Hamilton; Eduardo Ramacciotti
Journal:  Am J Ther       Date:  2013 Mar-Apr       Impact factor: 2.688

View more
  17 in total

Review 1.  Quality Improvement Initiatives in Inflammatory Bowel Disease.

Authors:  Sameer K Berry; Corey A Siegel; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2017-08

2.  Funding a smoking cessation program for Crohn's disease: an economic evaluation.

Authors:  Stephanie Coward; Steven J Heitman; Fiona Clement; Maria Negron; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Cynthia Seow; Yvette P Y Leung; Gilaad G Kaplan
Journal:  Am J Gastroenterol       Date:  2014-10-28       Impact factor: 10.864

3.  Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care.

Authors:  Kevin Barrett; Sonia Saxena; Richard Pollok
Journal:  Br J Gen Pract       Date:  2018-10       Impact factor: 5.386

4.  Clinical quality indicators in inflammatory bowel disease.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 5.  The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care.

Authors:  Jonathan A Beard; Diana L Franco; Benjamin H Click
Journal:  Curr Gastroenterol Rep       Date:  2020-01-30

Review 6.  Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Authors:  Ashwin N Ananthakrishnan; Tamara Donaldson; Karen Lasch; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

7.  Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis.

Authors:  Alyssa Caplan; Ryan McConnell; Fernando Velayos; Uma Mahadevan; Sara Lewin
Journal:  Dig Dis Sci       Date:  2022-04-07       Impact factor: 3.199

8.  Establishing Key Performance Indicators [KPIs] and Their Importance for the Surgical Management of Inflammatory Bowel Disease-Results From a Pan-European, Delphi Consensus Study.

Authors:  Pritesh S Morar; James Hollingshead; Willem Bemelman; Nick Sevdalis; Thomas Pinkney; Graeme Wilson; Malcolm Dunlop; R Justin Davies; Richard Guy; Nicola Fearnhead; Steven Brown; Janindra Warusavitarne; Cathryn Edwards; Omar Faiz
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

Review 9.  Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations.

Authors:  Edouard Louis; Iris Dotan; Subrata Ghosh; Liat Mlynarsky; Catherine Reenaers; Stefan Schreiber
Journal:  J Crohns Colitis       Date:  2015-05-18       Impact factor: 9.071

Review 10.  Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Authors:  Jill Mv Petkau; Bertus Eksteen
Journal:  Biologics       Date:  2016-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.